Acrivon Therapeutics(ACRV) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection (p = 0.009) from ongoing ACR-368 registrationalintent Phase 2b endometrial cancer study presented at ESMO - Endometrial cancer, a tumor type identified by AP3 as particularly sensitive to ACR-368 treatment, represents the first potential approval opportunit ...